IGXT - IntelGenx Technologies Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.4475
+0.0675 (+17.76%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.3800
Open0.3680
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3680 - 0.4560
52 Week Range0.3200 - 0.7600
Volume2,045,973
Avg. Volume430,722
Market Cap41.854M
Beta (5Y Monthly)1.69
PE Ratio (TTM)N/A
EPS (TTM)-0.1120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.10
  • GlobeNewswire

    IntelGenx Completes C$8.2 Million Equity Offering

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed its offering (the “Offering”) of 16,317,000 units (the “Units”) at a price of C$0.50 per Unit (the “Offering Price”) for gross proceeds of C$8,158,500. Each Unit consists of one share of common stock (the “Offered Shares”) and one warrant (a “Warrant”) entitling the holder to purchase one share of common stock of the Company at an exercise price of C$0.75 per share (a “Warrant Share”).

  • GlobeNewswire

    IntelGenx Announces Pricing of Equity Offering

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of up to 20,000,000 units, subject to a minimum offering of 10,000,000 units (the “Units”), for gross proceeds of between $5,000,000 and $10,000,000, assuming no exercise of the over-allotment option granted to the Agent (as defined below), at a price of $0.50 per Unit. Each Unit will consist of one share (each, an “Offered Share”) of common stock of the Company (“Common Stock”) and one warrant (each, a “Warrant”) to purchase one share of Common Stock at an exercise price of $0.75 per share (a “Warrant Share”). The Offering is being conducted on a commercially reasonable best efforts basis by Echelon Wealth Partners Inc. (the “Agent”) in the provinces of British Columbia, Alberta, Manitoba and Ontario.

  • GlobeNewswire

    IntelGenx Receives Health Canada Authorization to Proceed with New Amendment for Montelukast VersaFilm® Phase 2a Trial

    - Ongoing BUENA Trial to Continue at Increased Daily Dose - SAINT LAURENT, Quebec, Jan. 15, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in.

  • GlobeNewswire

    IntelGenx Provides Commercial Update on its Two Lead VersaFilm® Product Candidates, Cannabis-Infused Oral Film and RIZAPORT®

    “Because we believe this is an exciting product that will meet, if not exceed, consumer expectations, we think that we're well positioned to become a significant player in this expanding market as new product formats come online,” commented Dr. Horst G. Zerbe, CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx Enters Animal Health Market by Signing Feasibility Agreement for VetaFilm™ Platform

    SAINT LAURENT, Quebec, Jan. 09, 2020 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”) a leader in pharmaceutical films, today announced that it has entered into a.

  • GlobeNewswire

    IntelGenx Files Preliminary Short Form Prospectus in Connection With a Proposed Offering of Units

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has filed a preliminary short form prospectus (the “Prospectus”) with respect to an offering (the “Offering”) of units (“Units”) for a minimum of Cdn$4,000,000 and a maximum of Cdn$10,000,000 aggregate gross proceeds. Each Unit will consist of one share (an “Offered Share”) of the common stock of the Company (“Common Stock”) and one half of one common stock purchase warrant (each whole common stock purchase warrant, a “Warrant”).

  • GlobeNewswire

    IntelGenx Announces Issuance of Shares in Payment of Interest on Outstanding Debentures

    IntelGenx Technologies Corp. (IGX.V) (IGXT) (the “Company” or “IntelGenx”) announces that it intends to issue 415,178 common shares of the Corporation (the “Common Shares”) at a deemed price of CAD $0.73 per Common Share in payment of an aggregate of $303,080 in interest owing on the Corporation’s 8.00% convertible unsecured subordinated debentures due June 30, 2020 (the “Debentures”). Under the terms of the trust indenture governing the Debentures (the “Indenture”), the Corporation has the option to pay the semi-annual interest on the Debentures in either cash or Common Shares, subject to customary conditions set forth in the Indenture.

  • GlobeNewswire

    IntelGenx to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference

    SAINT LAURENT, Quebec, Dec. 03, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced.

  • GlobeNewswire

    IntelGenx Reports Third Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Nov. 07, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.

  • GlobeNewswire

    IntelGenx to Report Third Quarter 2019 Financial Results on November 7, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, Nov. 01, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced.

  • GlobeNewswire

    IntelGenx Initiates Scale-Up Work for Cannabis-Infused Oral Film Product

    SAINT LAURENT, Quebec, Oct. 31, 2019 -- IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has.

  • GlobeNewswire

    IntelGenx Announces FDA’s Acceptance of Resubmitted RIZAPORT® New Drug Application

    SAINT LAURENT, Quebec, Oct. 22, 2019 -- IntelGenx Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its.

  • GlobeNewswire

    IntelGenx Receives Positive DSMB Recommendation for Montelukast VersaFilm® Phase 2a Trial

    IntelGenx Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that an independent Data Safety Monitoring Board (“DSMB”) completed its first interim analysis of the ongoing Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). The DSMB reviewed compiled safety data from 25 subjects enrolled in the BUENA trial, 13 of which have completed 26 weeks of daily treatment. The DSMB did not raise any concerns regarding safety and recommended that the trial continue.

  • IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA
    Zacks

    IntelGenx (IGXT) Resubmits NDA for Migraine Candidate to FDA

    IntelGenx Corp. (IGXT) resubmits NDA for Rizaport VersaFilm for the treatment of acute migraines to the FDA.

  • GlobeNewswire

    IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

    IntelGenx Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has resubmitted its 505(b)(2) New Drug Application (“NDA”) for RIZAPORT® VersaFilm® for the treatment of acute migraines to the U.S. Food and Drug Administration (“FDA”). “Over the past several months, we have been working diligently to address the FDA’s questions and resubmit this NDA in a timely manner,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. On April 2, 2019, the Company announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding the NDA for RIZAPORT® VersaFilm® accepted by the Agency on November 20, 2018.

  • GlobeNewswire

    IntelGenx to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    IntelGenx Technologies Corp. (IGX.V)(IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that its CEO, Dr. Horst G. Zerbe, is scheduled to present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 1:45 p.m. ET at the Lotte New York Palace Hotel. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com.

  • IntelGenx (IGXT) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    IntelGenx (IGXT) Reports Q2 Loss, Misses Revenue Estimates

    IntelGenx (IGXT) delivered earnings and revenue surprises of -50.00% and -78.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    IntelGenx Reports Second Quarter 2019 Financial Results

    SAINT LAURENT, Quebec, Aug. 08, 2019 -- IntelGenx Technologies Corp. (TSX-V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today reported.

  • GlobeNewswire

    IntelGenx to Report Second Quarter 2019 Financial Results on August 8, 2019 – Conference Call to Follow

    SAINT LAURENT, Quebec, Aug. 01, 2019 -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its.

  • Will IntelGenx (IGXT) Report Negative Q2 Earnings? What You Should Know
    Zacks

    Will IntelGenx (IGXT) Report Negative Q2 Earnings? What You Should Know

    IntelGenx (IGXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    IntelGenx to Present at 12th Edition of Clinical Trials on Alzheimer’s Disease

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will present a Montelukast poster at the 12th edition of Clinical Trials on Alzheimer’s Disease (CTAD2019), to be held in San Diego, California, from December 4-7, 2019. The poster, entitled “The BUENA Study: A Phase 2a Clinical Trial to Test Safety and Efficacy of Montelukast VersaFilm®in Alzheimer’s Patients,” will be presented in collaboration with Prof. Dr. Ludwig Aigner’s group fromthe Paracelsus Medical University in Salzburg. “Our studies of Montelukast have garnered positive feedback from the Alzheimer’s disease community to-date, so we are looking forward to presenting our ongoing BUENA studyat CTAD2019,”said Dr. Horst G. Zerbe, CEO of IntelGenx.

  • GlobeNewswire

    IntelGenx Announces Addition of Peterborough’s Kawartha Centre as Montelukast VersaFilm® Phase 2a Clinical Trial Site

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, the Kawartha Centre has agreed to participate in IntelGenx’s Montelukast VersaFilm® Phase 2a BUENA clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). In addition, IntelGenx is honoured that renowned clinical researcher, Dr. Donald V. Doell, has agreed to serve as the site’s lead investigator. Based in Peterborough, Ontario, the Kawartha Centre’s corporate vision is to redefine healthy aging through expert, comprehensive, compassionate care for people facing memory loss, dementia and other related challenges.  In addition, Kawartha Centre’s vision is to improve the lives of patients, families, caregivers and communities from assessment and treatment to research and advocacy.

  • GlobeNewswire

    IntelGenx Announces Addition of Ottawa Montelukast VersaFilm® Phase 2a Clinical Trial Site; First Patient in Study Completes 26-Week Treatment

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it has added a new Ottawa site in the Montelukast VersaFilm® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”). BUENA is a randomized, double-blind, placebo-controlled Phase 2a “proof of concept” study designed to assess Montelukast VersaFilm® in approximately 70 patients with mild to moderate AD. BUENA will evaluate the safety, feasibility, tolerability, and efficacy of Montelukast buccal film following daily dosing for 26 weeks.

  • GlobeNewswire

    IntelGenx Receives First Shipment of Cannabis Extract from Tilray® for Production of Cannabis-Infused Oral Film

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), a leading oral drug delivery company, today provided an update on its cannabis-infused VersaFilm® product co-development program with Tilray, Inc. (TLRY) (“Tilray®”), a global leader in cannabis research, cultivation, production, and distribution. IntelGenx recently received the first shipment of cannabis extract from Tilray, providing it with sufficient quantities to commence batch production of cannabis-infused VersaFilm®. This supply of cannabis extract allows us to advance development and production of Cannabis-Infused VersaFilm® products, marking an important milestone for the co-development program.

  • GlobeNewswire

    IntelGenx to Join the Quebec Pavilion at BIO 2019 International Convention

    IntelGenx Corp. (IGX.V) (IGXT) (“IntelGenx”), leader in pharmaceutical films, today announced that it will be joining the Quebec Pavilion at Booth #2627 at BIO 2019 International Convention taking place on June 3-6, 2019 in Philadelphia, PA. IntelGenx will be promoting its contract development and manufacturing organization (“CDMO”) service capabilities utilizing its oral film and transdermal technologies. VersaFilm® and VetaFilm™ are IntelGenx’s proprietary oral drug delivery technology platforms for human and veterinary applications, respectively. They enable the development of oral films with potential to improve absorption, accelerate onset of action, reduce side effects, ease administration and improve patient compliance. Transdermal technology is the latest addition to IntelGenx’s drug delivery portfolio.